JA

Jules Adam

After I graduated with a master’s degree in European Law from the University of Tours, I decided to study journalism at the All Media Journalism Institute of Lille. During this time, I discovered the healthcare innovation ecosystem and enjoyed writing about it for Eurasanté, a French healthcare cluster.

I am interested in different subjects other than healthcare and biotechnology: cinema, sports, photography…

Journalism had always been at the back of my mind, and I am delighted to write for Labiotech as a junior reporter.

When I am not working you might find me on the tennis court or picking up the next piece of furniture I will renovate.

    Publications

    • Labiotech.eu
      29 articles

    Writes Most On

    BiotechBiotechnologyClinicalTrialsPharmaceuticalsDrugDevelopmentInnovationStartupsHealthCareMedicalResearchClinicalResearchArtificialIntelligenceDrugDiscoveryInvestmentFundingRegulatoryAffairsResearchAndDevelopmentAIMentalHealthCRISPREntrepreneurshipPharmaceuticalVentureCapitalCancerResearchLifeSciencesScientificResearchBiotechIndustryHealthcarePolicyHealthcareInnovationResearchMachineLearningPsychedelicsEntrepreneursHealthTechSupplyChainDataAnalyticsMedicalInnovationPersonalizedMedicineRegulatoryApprovalPharmaIndustryGeneTherapyInvestmentsMergersAndAcquisitionsStartupAIReshapingBiotechVirologyMentalWellbeingTherapyNeurimmuneRightsCareerGrowthMentalIllnessTreatment
    • Why are there only 20 cell and gene therapies in Europe?
      24 Jan—Labiotech.eu
      Photo credits: Wendelin Jacober Subscribe to our newsletter to get the latest biotech news! By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.* Business email* In 2020, we wrote about why there were only 11 cell and gene therapies in Europe. A bit over four years later, there are 20 – almost twice as many. But is it such a big improvement? Take a look overseas, the U.S. market currently counts...
    • What to look for in a biotech incubator
      6 Jan—Labiotech.eu
      Photo credits: Ivan Samkov Starting a biotech is a daunting task with a lot of parameters. And if you’re only starting, the chances are you don’t have all the resources and knowledge it takes to be successful or as efficient as possible yet. This is where biotech incubators can be useful, decisive even. But that doesn’t mean they’re all right for you. Selecting the right biotech incubator is a critical decision that can significantly influence a startup’s trajectory. The appropriate incubator...
    • Biotech in 2024: A retrospective
      10 Dec 2024—Labiotech.eu
      As 2024 comes to a close, and while we will soon be thinking about 2025 and the trends that will shape the biotech industry, now is a good time to look back at what happened this year. Earlier this year, we collected expert insight into what the year 2024 would look like for biotech – from AI reshaping the industry, and CRISPR’s growth potential to strong merger and acquisition (M&A) activity – which of those predicted trends became a reality in 2024? According to Artem Trotsyuk, operating...
    • —Labiotech.eu
    • Halloween biotech stories: Unveiling scientists’ worst fears
      31 Oct 2024—Labiotech.eu
      Photo credits: Beth Teutschmann What are you afraid of – spiders, clowns, heights? For me, it’s a bit of everything, but what terrifies me the most is what a deviant yet brilliant mind of biotechnology could accomplish. Imagine one second being faced with Dr. Frankenstein’s creature, or with one of Kronenberg’s horrific monsters. No, brilliant biotech minds should accomplish helpful things, or at least stay away from my list of fears so I can sleep at night. “The great thing about biotech is...